William J. Boyle - Malibu CA, US Eugene Medlock - Westlake CA, US John J. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA Medarex, Inc. - Princeton NJ
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
William J. Boyle - Malibu CA, US Eugene Medlock - Westlake CA, US John K. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA Medarex, Inc. - Princeton NJ
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
William J. Boyle - Malibu CA, US Eugene Medlock - Westlake CA, US John K. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA Medarex, Inc. - Princeton NJ
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
William J. Boyle - Malibu CA, US Eugene Medlock - Westlake CA, US John K. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA MEDAREX, INC. - Princeton NJ
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
John K. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont CA, US
Assignee:
MEDAREX, INC. - PRINCETON NJ AMGEN, INC. - THOUSAND OAKS CA
International Classification:
C07K 16/18
US Classification:
4241351, 4241741
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
Amgen Inc. - Thousand Oaks CA, US John K. Sullivan - Newbury Park CA, US Robin L. Elliott - Newbury Park CA, US Frank Martin - Newbury Park CA, US Haichun Huang - Fremont Park CA, US
Assignee:
MEDAREX, INC. - Princeton NJ AMGEN INC. - Thousand Oaks CA
International Classification:
C07K 16/24
US Classification:
4241581, 5303892, 5303873, 436501, 435 71
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.